How To Read A Retraction

Donmez et al. (2010) reported that SIRT1 suppressed Alzheimer’s disease in a mouse model by upregulating the ADAM 10 α-secretase gene via coactivation of the retinoic acid receptor, RARβ. Increased α-secretase bypassed the processing of APP by the β-secretase, thereby reducing the amyloid burden. It has come to our attention that several figures in the paper contain images in which gel lanes were spliced together without appropriate indication. There are also instances of image duplication. We believe that these errors do not affect the conclusions of experiments in the paper. Moreover, the finding that SIRT1 upregulates the ADAM 10 α-secretase in neurons was reported by Theendakara et al. (Theendakara, V., et al. [2013]. Proc. Natl. Acad. Sci. USA 110, 18303–18308), and the more detailed finding that SIRT1 and RARβ cooperate in neurons to activate ADAM 10 has also recently been reported by Lee et al. (Lee, H.R., et al. [2014]. J. Neurosci. Res. Published online June 5, 2014., thereby supporting our main conclusions. However, the level of care in figure preparation in Donmez et al. falls well below the standard that we expect, and we are therefore retracting the paper. We offer our sincerest apologies to the scientific community for these errors and for any inconvenience they may have caused.

== we faked the everloving fucke out of our data, but by sheer random dumb luck the conclusions we faked our data to support turned out to be maybe correct.


  1. Trebuchet says

    Just curious which major pharmaceutical company paid for this “research” in advance of releasing a new wonder drug.

  2. david says

    Trebuchet: “Just curious which major pharmaceutical company paid for this “research”” The full (retracted) paper is available online, where you can see that all the authors claim affiliation at “Paul F. Glenn Laboratory and Department of Biology, Massachusetts Institute of Technology.” The acknowledgements section reads “This work is supported by an American Parkinson Disease Association post-doctoral fellowship to G.D. and grants from the NIH and a gift from the Paul F. Glenn Foundation to L.G” There is plenty of academic fraud, fueled by publish-or-perish. There is absolutely no evidence that fraud is more common in pharma companies. Disclaimer: I work for a pharma.

  3. sciliz says

    @Trebuchet- In fairness, the way you’d activate SIRT1 would be resveratrol. The magical unicorn red wine compound. The pharma companies did try to capitalize on it, but so far have failed. Just drink more wine.

Leave a Reply

Your email address will not be published. Required fields are marked *